Moleculin Biotech Inc. has announced a significant advancement in its financial operations by entering into an At The Market Offering Agreement with Roth Capital Partners, LLC. The agreement, finalized on July 11, 2025, allows Moleculin to sell shares of its common stock, potentially raising up to $6.5 million. The proceeds from these sales will be directed towards working capital and general corporate purposes. Roth Capital will act as the sales agent, applying its trading expertise to facilitate the sales based on the company's instructions. Moleculin retains the flexibility to suspend or terminate the offering as needed. This strategic move underscores Moleculin's proactive approach to bolstering its financial resources and supporting its ongoing corporate initiatives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.